o-desmethylangolensin has been researched along with Osteoporosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, S; Fujioka, M; Ishimi, Y; Katsumata, S; Takeda, K; Uehara, M | 1 |
| Adlercreutz, H; Ishimi, Y; Katsumata, S; Masuyama, R; Ohtomo, T; Peñalvo, JL; Suzuki, K; Takeda, K; Uehara, M | 1 |
2 other study(ies) available for o-desmethylangolensin and Osteoporosis
| Article | Year |
|---|---|
Kanamycin inhibits daidzein metabolism and abilities of the metabolites to prevent bone loss in ovariectomized mice.
Topics: Administration, Oral; Animals; Biotransformation; Body Weight; Bone Density; Diet; Disease Models, Animal; Equol; Female; Femur; Humans; Isoflavones; Kanamycin; Mice; Organ Size; Osteoporosis; Ovariectomy; Phytoestrogens; Uterus | 2016 |
Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures.
Topics: Animals; Bone Density; Coculture Techniques; Dose-Response Relationship, Drug; Equol; Estrogens, Non-Steroidal; Female; Isoflavones; Lipid Metabolism; Mice; Mice, Inbred Strains; Osteoclasts; Osteoporosis; Ovariectomy; Random Allocation | 2008 |